ONVO - Organovo Holdings, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.4624
-0.0267 (-5.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.4891
Open0.5020
Bid0.4600 x 1100
Ask0.0000 x 900
Day's Range0.4600 - 0.5020
52 Week Range0.3700 - 1.5500
Volume1,437,797
Avg. Volume2,042,114
Market Cap60.217M
Beta (3Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire5 days ago

    Organovo to Present at Raymond James Life Sciences and MedTech Conference

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that Chief Executive Officer Taylor J. Crouch is scheduled to speak at the Raymond James Life Sciences and MedTech Conference in New York on Tuesday, June 18, 2019 at 1:15pm Eastern Time (ET).  The presentation will be simultaneously audio webcast at http://www.organovo.com.  The audio webcast will be archived for seven days following the conference.

  • GlobeNewswire19 days ago

    Organovo Collaborates With MCRI and Leiden University Medical Center to Develop Stem Cell-Based Bioprinted Tissue Treatments for Kidney Disease

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious diseases, today announced a collaboration with Professor Melissa Little at the Murdoch Children's Research Institute (“MCRI”), The Royal Children’s Hospital, Melbourne, Australia and Ton Rabelink at Universiteit Leiden (“LUMC”), Leiden, Netherlands. The project will expand the use of 3D bioprinted stem cell-based therapeutic tissues to applications aimed at treating end-stage renal disease.  This multi-organizational effort integrates Organovo’s leading bioprinting platform with MCRI’s advanced stem cell differentiation technology and LUMC’s cell lines and clinical expertise.  The collaboration has been made possible through generous funding from Stem Cells Australia and CSL Limited.

  • GlobeNewswire27 days ago

    Organovo Updates Key Clinical Development Goals; Company Reports Preliminary Fiscal Fourth-Quarter 2019 Results

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today updated its key clinical development goals and reported its preliminary fiscal fourth-quarter 2019 financial results.

  • GlobeNewswirelast month

    Organovo Announces Release Date for Preliminary Fiscal Fourth-Quarter 2019 Financial Results

    SAN DIEGO, May 17, 2019 -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Wednesday, May 22, 2019 at 5:00 p.m. Eastern Time (ET) to discuss.

  • GlobeNewswire2 months ago

    Organovo to Present at 2019 Cell & Gene Meeting on the Mediterranean

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that Chief Medical Officer, Dr. Steven G. Hughes, is scheduled to speak at the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 in Barcelona, Spain. Organovo is changing the shape of life science research and transforming medical care.

  • GlobeNewswire3 months ago

    Organovo to Participate in Nash Panel Discussion at 31st Annual Roth Conference

    Organovo Holdings, Inc. (ONVO) (“Organovo”) today announced that it will participate in a panel at the 31st Annual ROTH Conference, being held in Laguna Niguel, Ca. from March 17-19, 2019.  The Company will also participate in one-on-one meetings with investors who are registered to attend the conference.

  • GlobeNewswire4 months ago

    Organovo Appoints New Board Member

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that its board of directors has appointed one new member.  Ms. Carolyn Beaver, former Chief Financial Officer of Sequenom Inc., will join Organovo’s board, effective immediately.  Ms. Beaver’s appointment increases the number of Organovo directors to nine.

  • GlobeNewswire4 months ago

    Factors of Influence in 2019, Key Indicators and Opportunity within Fiserv, DTE Energy, Acacia Communications, Organovo, Presidio, and Power Integrations — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire4 months ago

    Organovo Affirms Key Clinical Development Goals; Company Reports Fiscal Third-Quarter 2019 Results

    Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019Submit first IND in calendar 2020 SAN DIEGO, Feb. 07, 2019 -- Organovo Holdings,.

  • GlobeNewswire5 months ago

    Organovo Announces Release Date for Fiscal Third-Quarter 2019 Financial Results

    SAN DIEGO, Jan. 17, 2019 -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, February 7, 2019 at 5:00 p.m. Eastern Time (ET) to.

  • GlobeNewswire7 months ago

    Organovo Partners With IIAM on Multi-Year Clinical Biomaterial Sourcing Agreement 

    Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that it has entered into a cell and tissue clinical sourcing agreement with the International Institute for the Advancement of Medicine (“IIAM”).  Under the terms of the agreement, IIAM will provide Organovo with donated organs that have not been utilized for transplantation with high potential benefit for generating the cell-based building blocks for Organovo’s therapeutic liver tissue development program.

  • GlobeNewswire7 months ago

    Organovo Affirms Key Clinical Development Goals; Company Reports Fiscal Second-Quarter 2019 Results

    Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019Second orphan designation anticipated in first half of calendar 2019Submit first.

  • ACCESSWIRE10 months ago

    Organovo Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Organovo Holdings, Inc. (NASDAQ: ONVO ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 9, 2018 at 5:00 PM Eastern ...

  • ACCESSWIRE11 months ago

    Free Pre-Market Technical Recap on ResMed and Three Additional Healthcare Stocks

    On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: OraSure Technologies Inc. (NASDAQ: OSUR), ResMed Inc. (NYSE: RMD), OpGen Inc. (NASDAQ: OPGN), and Organovo Holdings Inc. (NASDAQ: ONVO). On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 373,287 shares.